GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Everest Medicines Ltd (HKSE:01952) » Definitions » Equity Investments

Everest Medicines (HKSE:01952) Equity Investments


View and export this data going back to 2020. Start your Free Trial

What is Everest Medicines Equity Investments?

Equity Investments only applies to insurance companies.


Everest Medicines (HKSE:01952) Business Description

Traded in Other Exchanges
Address
1168 West Nanjing Road, 16th Floor, CITIC Pacific Plaza, Jing’an District, Shanghai, CHN, 200041
Everest Medicines Ltd is a biopharmaceutical company that integrates discovery, licensing, clinical development, commercialization, and manufacturing of potentially novel or differentiated therapies and vaccines to address critical unmet medical needs initially in the Asia Pacific markets and eventually around the world. Its product pipeline includes; Nefecon (TarpeyoTM), EVER001 (previously known as XNW1011), PTX-COVID19-B, Eravacycline (Xerava), EVER206 (also known as SPR206), and others.